- AU$278.59m
- AU$453.34m
- AU$271.92m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.02 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -11.6% | ||
| Dividend Yield (f) | 4.67% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.13 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.02 | ||
| EV to EBITDA | 6.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.07% | ||
| Return on Equity | 10.25% | ||
| Operating Margin | 15.97% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 183.6 | 192.29 | 213.59 | 254.96 | 271.92 | 263.82 | 273.52 | 13.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +12.08 | -6.12 | +17.73 | +1.95 | -0.52 | -17.7 | +5.56 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Monash IVF Group Limited is a provider of Assisted Reproductive Services (ARS). It offers a range of techniques used to assist patients experiencing infertility in achieving a clinical pregnancy, including reproductive genetic services. It is also a provider of specialized women's imaging services. It provides a range of specialist diagnostic obstetric and gynecological ultrasound and fertility treatment. Its segments consist of two operations: Australia IVF and Ultrasound, providing ARS, ultrasound and other related services. International IVF, providing ARS in Southeast Asia. Its business includes fertility solutions that provide fertility treatment and care; KL Fertility is a fertility specialist center; Monash IVF is a fertility research and treatment center; Monash IVF KPJ Johor is a full-service hospital-based fertility center, and Monash Ultrasound for Women provides tertiary level prenatal diagnostic services. Its business also includes Repromed and Sydney Ultrasound for Women.
Directors
- Richard Davis NEC (65)
- Michael Knaap CEO
- Malik Jainudeen CFO
- Denise Donati CEX
- Hamish Hamilton COO
- Pierre Haila CIO
- Fiona Allen CMO
- Anthony Gurney GMG
- Jonathan Whitty GMG
- Richard Henshaw EDR (80)
- Nicolette Curtis OTH
- Tedd Fuell OTH
- Ben Howat OTH
- Johannes Lagerwij OTH
- Loke May Kew OTH
- Shannon Neilsen OTH
- Peggy North OTH
- Rebecca Redden OTH
- Luk Rombauts OTH
- Deirdre Zander-fox OTH
- Neil Broekhuizen NID
- Josef Czyzewski NID
- Zita Peach NID
- Catherine West NID
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- April 30th, 2014
- Public Since
- June 26th, 2014
- No. of Employees
- 892
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 389,634,840
- Address
- Level 1, 510 Church St, Cremorne, RICHMOND, 3121
- Web
- https://www.monashivfgroup.com.au/
- Phone
- +61 394208235
- Auditors
- KPMG
Upcoming Events for MVF
Similar to MVF
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Careteq
Australian Stock Exchange - SEATS
FAQ
What is the Monash IVF share price?
As of Today at 22:08 UTC, shares in Monash IVF are trading at AU$0.72. This share price information is delayed by 15 minutes.
How has the Monash IVF share price performed this year?
Shares in Monash IVF last closed at AU$0.72 and the price had moved by -40.91% over the past 365 days. In terms of relative price strength the Monash IVF share price has underperformed the ASX All Ordinaries Index by -45.16% over the past year.
What are the analyst and broker recommendations for Monash IVF?
The overall consensus recommendation for Monash IVF is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Monash IVF dividend yield?
Monash IVF does not currently pay a dividend.
Does Monash IVF pay a dividend?
Monash IVF does not currently pay a dividend.
When does Monash IVF next pay dividends?
Monash IVF does not currently pay a dividend.
How do I buy Monash IVF shares?
To buy shares in Monash IVF you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Monash IVF?
As of the previous close price of AU$0.72, shares in Monash IVF had a market capitalisation of AU$278.59m.
Where are Monash IVF shares listed?
Here are the trading details for Monash IVF:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MVF
What kind of share is Monash IVF?
Based on an overall assessment of its quality, value and momentum Monash IVF is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Monash IVF share price forecast for 2025?
The analyst consensus target price for shares in Monash IVF is AU$0.87. That is 21.12% above the last closing price of AU$0.72.
Analysts covering Monash IVF currently have a consensus Earnings Per Share (EPS) forecast of AU$0.05 for the next financial year.
Find out moreWhat is the trend in the Monash IVF share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Monash IVF. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -14.37%.
As of the last closing price of AU$0.72, shares in Monash IVF were trading -19.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Monash IVF PE Ratio?
The Monash IVF PE ratio based on its reported earnings over the past 12 months is 13.02. The shares last closed at AU$0.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Monash IVF?
Monash IVF's management team is headed by:
- Richard Davis - NEC
- Michael Knaap - CEO
- Malik Jainudeen - CFO
- Denise Donati - CEX
- Hamish Hamilton - COO
- Pierre Haila - CIO
- Fiona Allen - CMO
- Anthony Gurney - GMG
- Jonathan Whitty - GMG
- Richard Henshaw - EDR
- Nicolette Curtis - OTH
- Tedd Fuell - OTH
- Ben Howat - OTH
- Johannes Lagerwij - OTH
- Loke May Kew - OTH
- Shannon Neilsen - OTH
- Peggy North - OTH
- Rebecca Redden - OTH
- Luk Rombauts - OTH
- Deirdre Zander-fox - OTH
- Neil Broekhuizen - NID
- Josef Czyzewski - NID
- Zita Peach - NID
- Catherine West - NID